NC
FLNA

NewSquare Capital’s Filana Therapeutics FLNA Stock Holding History

NewSquare Capital’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12
Closed -$294 – 846
2023
Q2 		$294 Hold
12
– – ﹤0.01% 732
2023
Q1 		$289 Hold
12
– – ﹤0.01% 764
2022
Q4 		$354 Buy
+12
New +$431 ﹤0.01% 684

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GCM
Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

NewSquare Capital's FLNA Position: Q3 2023 in Review

NewSquare Capital sold out of Filana Therapeutics (FLNA) in Q3 2023, closing a stake of 12 shares — an estimated $294 sold.

NewSquare Capital first reported a position in FLNA in Q4 2022 and held it in 3 quarters. The position peaked at $354 in Q4 2022. 140 funds tracked by Wall St. Rank hold FLNA as of Q3 2023.

  • NewSquare Capital reported no remaining Filana Therapeutics position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 12 Filana Therapeutics shares in Q3 2023, an estimated $294.
  • NewSquare Capital first reported a position in Filana Therapeutics in Q4 2022 and held it in 3 quarters.
  • NewSquare Capital's Filana Therapeutics position peaked at $354 in Q4 2022.
  • 140 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.